SEQUENOM! TOP ZAHLEN!! 4 CENT BESSER!!!!! - 500 Beiträge pro Seite

[ciena]

SEQUENOM Reports Second Quarter 2001 Financial Results
Product Demand Drives Revenue Growth; Disease Gene Discoveries Accelerate Downstream Momentum
SAN DIEGO, July 31 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM - news) today reported consolidated financial results for the three and six months ended June 30, 2001.

Revenue for the quarter ended June 30, 2001 was $7.4 million, compared to $1.9 million for the same period in 2000, primarily driven by MassARRAY(TM) product sales and revenue from genomics services provided to the Company`s collaborators. Revenue for the six-month period ended June 30, 2001 increased to $12.6 million, compared to $3.5 million for the same period in 2000.

Total costs and expenses for the quarter increased to $17.6 million from $10.0 million for the second quarter of 2000. Expense increase during the quarter was primarily driven by expansion of the Company`s disease gene discovery efforts at its high-throughput genotyping facility in San Diego. For the six-month period, expenses were $31.9 million compared to $23.0 million for the same period in 2000.

The net loss for the second quarter was $8.7 million, or $0.36 per diluted share, compared to a net loss of $5.6 million, or $0.23 per diluted share, for the second quarter of 2000. The net loss for the six-month period was $15.7 million, or $0.65 per diluted share, compared to a net loss of $20.0 million, or $0.86 per pro forma diluted share, for the same period in 2000.

On June 30, 2001, the Company held cash, cash equivalents and short-term investments totaling $114.3 million.

``We began selling our MassARRAY system in January 2000, and this is now our fourth consecutive quarter with revenues increasing at a growth rate of over 35 percent,`` said Steve Zaniboni, SEQUENOM`s Chief Financial Officer. ``We continue to meet a strong demand for our MassARRAY product line, which is largely accepted as the most powerful genotyping technology within this rapidly growing segment of the DNA analysis market. We are particularly pleased with consumables sales of more than three million tests purchased during the quarter, representing an increase of 50 percent compared to the previous quarter.``


Company highlights during the quarter included:

-- Expansion of candidate disease gene portfolio. Over the quarter,
SEQUENOM increased its portfolio of candidate disease genes from 30 to
more than 50. Each of these candidate disease genes is believed to be
associated with human diseases affecting large portions of the
population. The Company continues to expand its intellectual property
position to cover the candidate genes it discovers using its
populations genetics approach. The Company also offers services to
life science companies for genetic marker analysis and to
pharmaceutical companies to prioritize leads based on population
impact.
-- Transitioning disease gene discoveries into diagnostic and drug
development. SEQUENOM announced in June its in-house biotherapeutics
initiative, which should leverage maximum value from its disease gene
discoveries. The Company will select the most compelling targets to
transition into clinical development using in-house resources that will
be significantly expanded over the next 12 months. SEQUENOM intends to
license selected targets to pharmaceutical companies through
collaborative agreements. Also during the quarter, SEQUENOM announced
a collaboration with Morphochem AG to develop novel drug candidates for
type 2 diabetes and cancer. The collaboration will utilize
Morphochem`s unique chemical genomics approach to validate disease
genes discovered by SEQUENOM.
-- Strong demand for MassARRAY technology. SEQUENOM continues to build
upon its leadership position in providing high-throughput genotyping
systems, software and related consumables. The Company sold 16 systems
during the first half of 2001 for a total of 38 since the product`s
commercial launch at the beginning of 2000. New customers during the
quarter included BioServe Biotechnologies, Centagenetix, LGC Ltd.,
University of Massachusetts Medical School, Indiana University School
of Medicine, University of Texas Health Science Center, Wake Forest
University School of Medicine and Weizmann Institute of Science in
Israel.
-- Increased capabilities offered to MassARRAY customers. SEQUENOM
introduced two new products during the quarter that each offer improved
efficiency and increased throughput to MassARRAY customers. The
SpectroPOINT(TM) sample spotter significantly increases the rate of
transferring samples in preparation for large-scale genotyping. The
SpectroPOINT is capable of spotting nearly 4,000 samples in a single
run without the need for user intervention. The newly introduced
SpectroTYPER RT(TM) data analysis software provides real-time data and
automated calibration that reduce the analysis per sample to less than
two seconds.

Company organizational highlights include:

-- Proposed merger with Gemini Genomics. The combination of SEQUENOM`s
technology and disease gene discovery program with Gemini`s clinical
resources is expected to significantly expand SEQUENOM`s ability to
perform disease gene association studies. SEQUENOM believes that the
merger with Gemini should provide a pipeline of validated, high-impact
genes for downstream development of diagnostic and therapeutic
products. SEQUENOM expects the merger to be finalized in late
September.
-- Expansion into Biotherapeutics. SEQUENOM, Inc. will operate SEQUENOM
Genomics and SEQUENOM Biotherapeutics. SEQUENOM Genomics will focus on
MassARRAY product sales, genomics collaborations, and disease gene
identification and validation programs. SEQUENOM Biotherapeutics will
apply technologies to transition disease genes into drugs and
diagnostics. Partnering opportunities may exist at any point along the
therapeutic development process, with a focus on licensing later-stage,
higher-value discoveries. SEQUENOM Biotherapeutics will also seek
strategic partners to leverage additional value from Gemini`s extensive
clinical resources.


``By now it is clear that market demand has established SEQUENOM`s MassARRAY product line as the leading large-scale genetic analysis technology. Now we are using this technology in combination with a population genetics strategy to build what we believe will be one of the most valuable intellectual property positions in the industry -- namely on genes associated with major human diseases,`` said Toni Schuh, Ph.D., SEQUENOM`s President and Chief Executive Officer.

``MassARRAY enables a systematic filtering strategy to identify

[M.Haze]

@ciena

wie geht es denn weiter? , mit dem letzten Satz, meine ich.

Noch was: Gibt es hier irgendwelche Insider, die wissen
wieviele Basenpaar lange DNA mittlerweile ueber die
MALDI-TOF sequenziert werden koennen?

Mein letzter Stand ist etwa 4-5 Jahre alt, und da
waren es ueber 1000, vielleicht auch 3- bis 4-tsd.

Gruesse,
M.Haze

[ciena]

hallo haze
hier der link dazu!
http://biz.yahoo.com/prnews/010731/latu019.html

[ciena]

vorbörslich schon 10,56$!!!
es geht loß

[toninioa]

After Hours Trade Reporting
Monday July 30
After Hours Most Active

After Hours
Last:
$10.25

After Hours
Best Bid:
$10.25

After Hours
High:
$10.25
After Hours
Volume:
700

After Hours
Best Ask:
$18

After Hours
Low:
$10.25


After Hours
Time (ET)
After Hours
Price
After Hours
Share Volume
16.07
$ 10.25
700

[M.Haze]

Interessant, wie es hier in Deutschland die Kurse staerker
anzogen als in Amiland. Weiss hier jemand mehr? Vielleicht
zocken hier ein paar Bekannte des guten alten Prof. Koester....

Kleine Frage an ciena und co:

Wie seit Ihr auf dieses aussergewoehnliche Unternehmen
gekommen?


Gruss
M.Haze